Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts

Anna Maria Raiola, Alida Dominietto, Carmen di Grazia, Teresa Lamparelli, Francesca Gualandi, Adalberto Ibatici, Stefania Bregante, Maria Teresa Van Lint, Riccardo Varaldo, Anna Ghiso, Marco Gobbi, Angelo Michele Carella, Alessio Signori, Federica Galaverna, Andrea Bacigalupo

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

We studied 459 consecutive patients with hematologic malignancies, median age 44years (range, 15 to 71years), who underwent transplantation with grafts from identical sibling donors (SIB; n=176), matched unrelated donors (MUD; n=43), mismatched unrelated donors (mmUD; n=43), unrelated cord blood (UCB; n=105) or HLA-haploidentical family donors (HAPLO; n=92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD, mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69%). Advanced disease phase was more frequent, but not significantly so, in the HAPLO and mmUD groups (P=08). Acute GVHD grade II-IV was significantly less frequent in the HAPLO, UCB, and MUD groups (14% to 21%) compared with the SIB (31%) and mmUD (42%) groups (P

Original languageEnglish
Pages (from-to)1573-1579
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number10
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Unrelated Donors
Graft vs Host Disease
Cyclosporine
Siblings
Transplantation
Tissue Donors
Transplants
Antilymphocyte Serum
Hematologic Neoplasms
Fetal Blood
Methotrexate
Cyclophosphamide
Conditioning (Psychology)

Keywords

  • Allogeneic transplant
  • Cord blood
  • Haploidentical
  • Unrelated

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

@article{c0307f809c7e48df93ad10f9d68fcc0f,
title = "Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts",
abstract = "We studied 459 consecutive patients with hematologic malignancies, median age 44years (range, 15 to 71years), who underwent transplantation with grafts from identical sibling donors (SIB; n=176), matched unrelated donors (MUD; n=43), mismatched unrelated donors (mmUD; n=43), unrelated cord blood (UCB; n=105) or HLA-haploidentical family donors (HAPLO; n=92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD, mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69{\%}). Advanced disease phase was more frequent, but not significantly so, in the HAPLO and mmUD groups (P=08). Acute GVHD grade II-IV was significantly less frequent in the HAPLO, UCB, and MUD groups (14{\%} to 21{\%}) compared with the SIB (31{\%}) and mmUD (42{\%}) groups (P",
keywords = "Allogeneic transplant, Cord blood, Haploidentical, Unrelated",
author = "Raiola, {Anna Maria} and Alida Dominietto and {di Grazia}, Carmen and Teresa Lamparelli and Francesca Gualandi and Adalberto Ibatici and Stefania Bregante and {Van Lint}, {Maria Teresa} and Riccardo Varaldo and Anna Ghiso and Marco Gobbi and Carella, {Angelo Michele} and Alessio Signori and Federica Galaverna and Andrea Bacigalupo",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.bbmt.2014.05.029",
language = "English",
volume = "20",
pages = "1573--1579",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts

AU - Raiola, Anna Maria

AU - Dominietto, Alida

AU - di Grazia, Carmen

AU - Lamparelli, Teresa

AU - Gualandi, Francesca

AU - Ibatici, Adalberto

AU - Bregante, Stefania

AU - Van Lint, Maria Teresa

AU - Varaldo, Riccardo

AU - Ghiso, Anna

AU - Gobbi, Marco

AU - Carella, Angelo Michele

AU - Signori, Alessio

AU - Galaverna, Federica

AU - Bacigalupo, Andrea

PY - 2014/10/1

Y1 - 2014/10/1

N2 - We studied 459 consecutive patients with hematologic malignancies, median age 44years (range, 15 to 71years), who underwent transplantation with grafts from identical sibling donors (SIB; n=176), matched unrelated donors (MUD; n=43), mismatched unrelated donors (mmUD; n=43), unrelated cord blood (UCB; n=105) or HLA-haploidentical family donors (HAPLO; n=92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD, mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69%). Advanced disease phase was more frequent, but not significantly so, in the HAPLO and mmUD groups (P=08). Acute GVHD grade II-IV was significantly less frequent in the HAPLO, UCB, and MUD groups (14% to 21%) compared with the SIB (31%) and mmUD (42%) groups (P

AB - We studied 459 consecutive patients with hematologic malignancies, median age 44years (range, 15 to 71years), who underwent transplantation with grafts from identical sibling donors (SIB; n=176), matched unrelated donors (MUD; n=43), mismatched unrelated donors (mmUD; n=43), unrelated cord blood (UCB; n=105) or HLA-haploidentical family donors (HAPLO; n=92). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate in the SIB recipients; antithymocyte globulin for the MUD, mmUD, and UCB recipients; and post-transplantation cyclophosphamide, cyclosporine, and mycophenolate in the HAPLO recipients. Conditioning regimens were mostly myeloablative (69%). Advanced disease phase was more frequent, but not significantly so, in the HAPLO and mmUD groups (P=08). Acute GVHD grade II-IV was significantly less frequent in the HAPLO, UCB, and MUD groups (14% to 21%) compared with the SIB (31%) and mmUD (42%) groups (P

KW - Allogeneic transplant

KW - Cord blood

KW - Haploidentical

KW - Unrelated

UR - http://www.scopus.com/inward/record.url?scp=84912523216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912523216&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.05.029

DO - 10.1016/j.bbmt.2014.05.029

M3 - Article

C2 - 24910379

AN - SCOPUS:84912523216

VL - 20

SP - 1573

EP - 1579

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -